Until the recent FDA approval of sodium‐glucose cotransporter 2 (SGLT2) inhibitors, renin–angiotensin system (RAS) inhibitors were the only pharmacological drug class that have been consistently proven to slow CKD progression and lower the risk of end stage renal disease (ESRD) (Hou et al., 2006; Ruggenenti et al., 1999), and no treatment has been shown to be effective at stopping or reversing CKD progression. The gene discussed is SLC5A2; the disease is chronic kidney disease.